跳至主要内容
临床试验/NCT01477008
NCT01477008已完成不适用

A Prospective, Multi-Center, Randomized Clinical Trial Comparing the Biphasic Cartilage Repair Implant to Marrow Stimulation in the Treatment of Focal Chondral and Osteochondral Lesions of the Knee

BioGend Therapeutics Co.Ltd11 个研究点 分布在 1 个国家目标入组 92 人开始时间: 2011年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
92
试验地点
11
主要终点
IKDC-2000 Subjective Knee Evaluation

研究概览

简要总结

The purpose of this trial is to evaluate the safety and effectiveness of the Biphasic Cartilage Repair Implant (BiCRI) compared to marrow stimulation in the treatment of chondral and osteochondral lesions located on the medial femoral condyle, lateral femoral condyle, or trochlea of the knee. The hypothesis is that the BiCRI provides an improvement in pain and function as compared to baseline, that is no worse than marrow stimulation at 1 year.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
— 至 55 Years(Child, Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Male or female presenting with a single, symptomatic chondral or osteochondral lesion of the medial or lateral femoral condyles or the trochlea requiring primary surgical intervention
  • •Skeletally mature (epiphyses are confirmed to be closed on x-ray)
  • •ICRS grade 3-4 lesion, Outerbridge grade 4, or OCD grades 3-4
  • •Lesion size requires no more than 2 implants (assuming patient were to be randomized to the treatment group). Lesion size will be assessed at the time of the study procedure for all subjects. If the size of the lesion is appropriate for 1 or 2 implants the patient will be randomized. If the lesion is found to be too large the patient will not be included in the trial, but will be treated according to standard of care. Lesion sizes that are considered appropriate include the following:
  • •Lesion is 3mm x 3mm or larger and can be completely covered by the small (12.5mm diameter) sizer (excluding small fissures). This lesion should be treated with 1 implant. or
  • •Lesion is 3mm x 3mm or larger and cannot be covered by the small sizer, but can be completely covered by the large (oval shaped) sizer (excluding small fissures). This lesion should be treated with 2 implants.
  • •Willing and able to refrain from taking pain medications (including: narcotic and non-steroidal anti-inflammatory drugs) for 7 days prior to the baseline preoperative visit and for 7 days prior to the 12-month postoperative visit (i.e., a "wash out" period)
  • •Willing and able to return for follow-up over a one year post-operative period
  • •Willing and able to comply with all postoperative guidelines

排除标准

  • •≥ 55 years old
  • •Lesions > grade II on the articular surface of the tibia or patella
  • •Kissing lesions (defined as an opposing lesion > grade II on the surface of the tibia or patella). Lesion ≤ grade II on opposing surface would be acceptable.
  • •Prior surgical treatment of the lesion
  • •Lesion would require more than 2 implants (assuming patient were to be randomized to the treatment group). Lesion sizes that are not considered appropriate include the following:
  • •Lesion is smaller than 3mm x 3mm
  • •Lesion cannot be completely covered by the large sizer
  • •Lesion will require bone grafting
  • •Rheumatoid arthritis and other inflammatory arthritis
  • •Concomitant comorbidities, such as:
  • •ACL instability that will not be corrected before or during the study procedure ("ACL instability" defined as the presence of a positive "pivot shift" test)
  • •Significant knee instability that will not be corrected before or during the study procedure
  • •Significant malalignment (varus or valgus deformity, patellar malalignment) that will not be corrected before or during the study procedure. Significant malalignment defined as:
  • •Any joint space narrowing as compared to the same compartment in the contralateral knee.
  • •Mechanical axis alignment outside the tibial spines.
  • •Patellofemoral subluxation on sunrise view.
  • •History of patellar dislocation or subluxation.
  • •Severe meniscal damage ("Severe meniscal damage" defined as > 50% of the meniscus missing or a radial tear extending to the meniscal-synovial junction)
  • •Knee stiffness, defined as:
  • •Flexion contracture >10°
  • •Flexion degree < 115°
  • •Body Mass Index (BMI) > 35.0
  • •Local or systemic infection, not including asymptomatic urinary tract infection if treated with antibiotics preoperatively
  • •Pregnancy or breast feeding
  • •Patient is involved in a personal litigation (e.g. Worker's Compensation lawsuit) that relates to their knee surgery
  • •Patient is actively participating in another medical device, drug, or biologic investigation (active defined as within the last 30 days)
  • •Patient otherwise meets the study criteria but refuses to consent in writing to participate in the study

研究组 & 干预措施

BiCRI

Experimental

BiPhasic Cartilage Repair Implant

干预措施: BiPhasic Cartilage Repair Implant (Device)

Marrow Stimulation

Active Comparator

Microfracture or Subchondral Drilling

干预措施: Marrow Stimulation (Procedure)

结局指标

主要结局

IKDC-2000 Subjective Knee Evaluation

时间窗: 12 months

Subjective evaluation of knee pain and function (will be captured at preop and each postop visit through 12 months)

次要结局

  • Knee Injury and Osteoarthritis Outcome Score (KOOS)(Preop, 6 weeks, 3 months, 6 months, and 12 months)
  • Arthroscopy with biopsy(12 months)
  • IKDC-2000 Knee Examination Form(Preop, 6 weeks, 3 months, 6 months, and 12 months)
  • IKDC-2000 Current Health Assessment Form(Preop, 6 weeks, 3 months, 6 months, and 12 months)
  • Radiographs(Preop, immediate postop, 6 weeks, 3 months, 6 months, 12 months)
  • Adverse Events(Treatment through 12 months)
  • Magnetic Resonance Imagining (MRI)(Preop and 12 months)
  • Pain (VAS): sitting, standing, and squatting(Preop, 6 weeks, 3 months, 6 months, and 12 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验